tibulizumab
tibulizumab: developed by 1 company · 1 clinical trial tracked.
tibulizumab evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could tibulizumab → ZURA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zura Bio Ltd (ZURA) Systemic Sclerosis (SSc) | Phase 2 |
Clinical Trials (1)
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis
Primary endpoint: [Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks
Frequently asked questions
Who is developing tibulizumab?
tibulizumab is being developed by Zura Bio Ltd.
How many clinical trials involve tibulizumab?
BioSniper tracks 1 clinical trial involving tibulizumab.